• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Brain Cancer  (Glioblastoma Multiforme): Disease and Pipeline Analysis
 

Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis

on

  • 414 views

This report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a view of the glioblastoma multiforme (brain cancer) market not available elsewhere. This ...

This report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a view of the glioblastoma multiforme (brain cancer) market not available elsewhere. This reports gives an overview of the current and future brain cancer clinical development market, the activities of the key market players, and outlines trial and commercial regulatory environments.

Statistics

Views

Total Views
414
Views on SlideShare
413
Embed Views
1

Actions

Likes
0
Downloads
0
Comments
0

1 Embed 1

http://www.slideee.com 1

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Brain Cancer  (Glioblastoma Multiforme): Disease and Pipeline Analysis Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis Document Transcript

    • EW PR EV I Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis Info@ISRreports.com ©2014 Industry Standard Research www.ISRreports.com
    • act with confidence Report Overview This report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a view of the glioblastoma multiforme (brain cancer) market not available elsewhere. This reports gives an overview of the current and future brain cancer clinical development market, the activities of the key market players, and outlines trial and commercial regulatory environments. 57 Major Sections: 1. Disease Overview Companies Included 12 2. Commercial Rationale 59 4. Clinical Development Pipeline 3. Environmental Analysis Countries Analyzed 5. The Clinical Trial Environment Pages What you will learn in this report: • Global and country-specific incidence rates for glioblastoma multiforme • Active development pipeline, including promising new therapies currently in Early and Late Phases of development • Country-specific analysis of clinical trial environments for new glioblastoma multiforme therapies How you can use this report: • Identify and enhance commercial and development opportunities with an in-depth and current analysis of the global glioblastoma multiforme market • Understand how products currently in development could impact this market and how large and small pharma is involved • Assess the competition with an analysis and summary of companies playing in this space Valuable for: • Brand Managers • Portfolio Managers • Research & Development • Managed Markets NEXT: List of Companies Included www.ISRreports.com ©2014 | Preview of: Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis 2
    • act with confidence Companies Included: Descriptions of product names, mechanism of actions (MOA), and highest development phase for the following companies: • • • • • • • • • • • • • • • • • • • AbbVie Actelion Pharma Activartis Aduro Biotech Advantagene Agenus Amgen Angiochem Antisense Pharma Apogenix Archer Biosciences Arno Therapeutics Ascenta Therapeutics AstraZeneca (MedImmune) BristolMeyersSquibb Cell Therapeutics Celldex Therapeutics CytoVac A/S DelMar Pharma • • • • • • • • • • • • • • • • • • • Dendreon Diffusion Pharma DNAtrix Inc Eisai Eli Lilly (Imclone) EMD Serono EnGenIC Erimos Pharma Genentech GW Pharma Immatics Biotechnologies ImmunoCellular Therapeutics Innocell Corp Lentigen Merck (Schering-Plough) Merck KGaA Northwest Biotherapeutics Novartis NovaRx • • • • • • • • • • • • • • • • • • • Oncolytics Biotech Oncothyreon Oncovir Inc. Peregrine Pharma Plexxikon Roche Sangamo Biosciences Sanofi (Exelixis) Sanofi Aventis StemLine Therapeutics Tau Therapeutics Thallion Pharma Threshold Pharma To-BBB technologies BV Tocagen TVAX Biomedical Valycyte VBL Therapeutics Visualase Inc. • • • • India Italy Japan Russia • • • • South Korea Spain United Kingdom United States Regions Analyzed: • • • • Brazil China France Germany NEXT: Table of Contents and Sample Pages www.ISRreports.com ©2014 | Preview of: Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis 3
    • act with confidence Table of Contents For table of contents and additional sample pages, download the full preview from our website: http://www.isrreports.com/product/brain-cancer-glioblastoma-multiformedisease-pipeline-analysis/ www.ISRreports.com ©2014 | Preview of: Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis 4
    • act with confidence Sample Page Introduction act with confidence disease & Development BRAIN CANCER Glioblastoma Multiforme (GBM) one of the deadliest cancer types. 5y e r a v Sur ival e at R r tumo s NS Rapid tumor growth, highly resistant tumors, and a lack of effective therapies contribute to making this onstitute as c a m imately 30 rox % pp Gl io GBM is the most common and most aggressive form of primary malignant brain tumor. Breast Cancer: 89% Colorectal: 64% Glioblastoma: 4.8% Lung: 15% Prostate: 99% rain an dC all b of 240,000 people are diagnosed with GBM globally each year. That’s equivalent to the population of Durham, NC. GBM is classified as an that’s orphan disease. This is defined as a disease that affects fewer than 200,000 people (in the U.S.). 2-3 cases per 100,000 adults Without treatment, the mean life expectancy is approximately 4.5 months. With standard of care treatment average life expectancy rises to approximately 15 months. Potential therapies can be eligible for Orphan Drug Designation, which allows the developing company to receive tax breaks and market exclusivity upon approval of the therapy. 76 GBM clinical trials were started in 2013 GBM is slightly more common in males and slightly more common in Caucasians (in US). 50 potential new therapies in active development, positive results in early stage trials. These new therapies include: • Immunotherapeutic Vaccines • Anti-Angiogenesis • Gene Therapy • Cell Signaling Pathway Inhibitors • Cytotoxics 58 PHARMA & biotech companies have sponsored GBM trials since 2010. Sources: ISR Reports, brain�mgh�harvard�edu, cancer�org, http://visual�ly/brain-cancer-infographic, www�mdanderson�org, seer�cancer�gov www.ISRreports.com ©2014 | Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis 5 www.ISRreports.com ©2014 | Preview of: Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis This is an enterprise-wide license and this file is not to be distributed beyond the terms of this agreement. For information on the license holder, please contact ISR (info@ISRreports.com). 5
    • act with confidence Sample Page For table of contents and additional sample pages, download the full preview from our website: http://www.isrreports.com/product/brain-cancer-glioblastoma-multiformedisease-pipeline-analysis/ www.ISRreports.com ©2014 | Preview of: Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis 6
    • act with confidence Ordering Information For pricing and orderng information, please visit our website: http://www.isrreports.com/product/brain-cancer-glioblastoma-multiformedisease-pipeline-analysis/ Save on this, or any ISR report, by registering a free account Register now • Receive a $250 instant credit towards any ISR report • Earn 10% credit towards all future purchases • Receive advanced notifications on ISR’s latest reports and free resources About Industry Standard Research Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries.  With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.    For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www. ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports. www.ISRreports.com ©2014 | Preview of: Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis 7
    • The ISR Difference act with confidence Custom-quality syndicated market research www.ISRreports.com ISR's Reports vs. The Common Syndicated Report How confident are you? Research methods vs. vs. Mostly primary research; always appropriate for the topic One size fits all; usually publically available data Data Collection ISR's proprietary data collection tools and channels support fast, high quality data collection vs. Struggle to recruit the right targets and enough of them Respondents vs. Sophisticated screening ensures genuine decision-makers Undisclosed methodologies and respondent demographics Sample Sizes vs. Robust sample sizes that instill confidence Often insufficient industry representation that leaves you defending results Analysts Decades of experience means more insights that are immediately usable vs. vs. Junior analysts capable of reporting numbers www.ISRreports.com ©2014 | Preview of:©2013Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis www.ISRreports.com Brain | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 8